Cargando…

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been widely used in the treatment of locally advanced non-small cell lung cancer (NSCLC). The phenomenon of pseudoprogression in targeted therapy in EGFR-mutation NSCLC patients is rare. Here, we reported an EGFR-mutation-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Fei, Wang, Yao, Gao, Yongsheng, Meng, Xiangjiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468776/
https://www.ncbi.nlm.nih.gov/pubmed/36110968
http://dx.doi.org/10.3389/fonc.2022.971192
_version_ 1784788492055740416
author Ren, Fei
Wang, Yao
Gao, Yongsheng
Meng, Xiangjiao
author_facet Ren, Fei
Wang, Yao
Gao, Yongsheng
Meng, Xiangjiao
author_sort Ren, Fei
collection PubMed
description Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been widely used in the treatment of locally advanced non-small cell lung cancer (NSCLC). The phenomenon of pseudoprogression in targeted therapy in EGFR-mutation NSCLC patients is rare. Here, we reported an EGFR-mutation-positive lung adenocarcinoma patient who was admitted to a hospital for cough and chest distress accompanied by shortness of breath. He underwent four cycles of chemotherapy with pemetrexed combined with carboplatin and concurrent radiotherapy in the third and fourth cycles. Then, he was treated by osimertinib maintenance therapy. After 11.5 months of osimertinib treatment, he was assessed to progressive disease by computed tomography. He underwent fiber bronchoscopy, and the biopsy pathology showed extensive necrosis without tumor cells. Until now, the patient has continued on osimertinib for 7 months without relapse or metastasis. As far as we know, we are the first to report pseudoprogression in osimertinib maintenance after definitive chemoradiation. This study reminds the clinicians to distinguish pseudoprogression from osimertinib-induced progression and avoid abandoning effective treatments.
format Online
Article
Text
id pubmed-9468776
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94687762022-09-14 Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report Ren, Fei Wang, Yao Gao, Yongsheng Meng, Xiangjiao Front Oncol Oncology Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been widely used in the treatment of locally advanced non-small cell lung cancer (NSCLC). The phenomenon of pseudoprogression in targeted therapy in EGFR-mutation NSCLC patients is rare. Here, we reported an EGFR-mutation-positive lung adenocarcinoma patient who was admitted to a hospital for cough and chest distress accompanied by shortness of breath. He underwent four cycles of chemotherapy with pemetrexed combined with carboplatin and concurrent radiotherapy in the third and fourth cycles. Then, he was treated by osimertinib maintenance therapy. After 11.5 months of osimertinib treatment, he was assessed to progressive disease by computed tomography. He underwent fiber bronchoscopy, and the biopsy pathology showed extensive necrosis without tumor cells. Until now, the patient has continued on osimertinib for 7 months without relapse or metastasis. As far as we know, we are the first to report pseudoprogression in osimertinib maintenance after definitive chemoradiation. This study reminds the clinicians to distinguish pseudoprogression from osimertinib-induced progression and avoid abandoning effective treatments. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9468776/ /pubmed/36110968 http://dx.doi.org/10.3389/fonc.2022.971192 Text en Copyright © 2022 Ren, Wang, Gao and Meng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ren, Fei
Wang, Yao
Gao, Yongsheng
Meng, Xiangjiao
Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
title Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
title_full Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
title_fullStr Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
title_full_unstemmed Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
title_short Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report
title_sort pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage iii non-small cell lung cancer: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468776/
https://www.ncbi.nlm.nih.gov/pubmed/36110968
http://dx.doi.org/10.3389/fonc.2022.971192
work_keys_str_mv AT renfei pseudoprogressionwithosimertinibafterdefinitivechemoradiationinunresectableepidermalgrowthfactorreceptormutationpositiveofstageiiinonsmallcelllungcanceracasereport
AT wangyao pseudoprogressionwithosimertinibafterdefinitivechemoradiationinunresectableepidermalgrowthfactorreceptormutationpositiveofstageiiinonsmallcelllungcanceracasereport
AT gaoyongsheng pseudoprogressionwithosimertinibafterdefinitivechemoradiationinunresectableepidermalgrowthfactorreceptormutationpositiveofstageiiinonsmallcelllungcanceracasereport
AT mengxiangjiao pseudoprogressionwithosimertinibafterdefinitivechemoradiationinunresectableepidermalgrowthfactorreceptormutationpositiveofstageiiinonsmallcelllungcanceracasereport